Market cap
$157 Mln
Revenue (TTM)
$21 Mln
P/E Ratio
--
P/B Ratio
2.1
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-45 Mln
-
ROE
-0.6 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-2.3
-
Debt to Equity
0.1
-
Book Value
$--
-
EPS
$-2
-
Face value
--
-
Shares outstanding
21,981,900
5 Years Aggregate
CFO
$-39.68 Mln
EBITDA
$-77.55 Mln
Net Profit
$-79.92 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
FStar Therapeutics Inc (FSTX)
| 12.7 | 44.7 | 34.8 | 138.9 | 30.5 | -34.9 | -- |
|
BSE Sensex*
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|---|---|---|---|---|---|---|
|
FStar Therapeutics Inc (FSTX)
| 25.9 | -49.1 | 56.2 | -84.8 | -22.6 | 68.2 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
FStar Therapeutics Inc (FSTX)
|
7.1 | 156.5 | 21.2 | -44.8 | -209.2 | -61.7 | -- | 2.1 |
| 13.7 | 914.4 | 0.0 | -175.9 | -- | -106.8 | -- | 5.6 | |
| 12.4 | 2,195.3 | 549.1 | 17.9 | -6.3 | 1.4 | 126.3 | 1.7 | |
| 4.7 | 1,105.5 | 4.5 | -340.2 | -518.6 | 501.4 | -- | 2.1 | |
| 12.8 | 518.9 | 0.0 | -29.0 | 0.0 | -20.4 | -- | 1.8 | |
| 17.5 | 2,204.8 | 65.4 | -94.4 | -108.2 | -16.1 | -- | 3.9 | |
| 11.7 | 838.7 | 366.5 | 9.3 | 8.3 | 3.4 | 84.6 | 3.1 | |
| 3.6 | 614.9 | 4.1 | -187.9 | -4,613.1 | -233.9 | -- | 0.3 | |
| 13.4 | 824.8 | 0.6 | -59.9 | -9,892.6 | -118.9 | -- | 21.3 | |
| 26.1 | 2,920.0 | 449.6 | -188.2 | -41.1 | -28.5 | -- | 4.8 |
Shareholding Pattern
View DetailsAbout FStar Therapeutics Inc (FSTX)
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is... being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody that is in Phase 1 clinical trial targeting the costimulatory CD137 receptor and the inhibitory PD-L1 ligand. In addition, the company is also evaluating FS120 and SB 11285 for patients with advanced cancers, which are under Phase 1 clinical trials. F-star Therapeutics, Inc. was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom. As of March 8, 2023, F-star Therapeutics, Inc. operates as a subsidiary of invoX Pharma Limited. Read more
-
Pres, CEO & Director
Dr. Eliot Richard Forster M.B.A., Ph.D.
-
Pres, CEO & Director
Dr. Eliot Richard Forster M.B.A., Ph.D.
-
Headquarters
Cambridge
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for FStar Therapeutics Inc (FSTX)
What is the current share price of FStar Therapeutics Inc (FSTX) Today?
The share price of FStar Therapeutics Inc (FSTX) is $7.12 (NASDAQ) as of 17-Mar-2023 09:30 EDT. FStar Therapeutics Inc (FSTX) has given a return of 30.54% in the last 3 years.
What is the current PB & PE ratio of FStar Therapeutics Inc (FSTX)?
Since, TTM earnings of FStar Therapeutics Inc (FSTX) is negative, P/E ratio is not available.
The P/B ratio of FStar Therapeutics Inc (FSTX) is 2.13 times as on 17-Mar-2023, a 56 discount to its peers’ median range of 4.82 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2021 |
-2.73 |
0.88 |
2020 |
-1.16 |
0.69 |
2019 |
-- |
-- |
2018 |
-- |
-- |
2017 |
-- |
-- |
What is the 52 Week High and Low of FStar Therapeutics Inc (FSTX)?
The 52-week high and low of FStar Therapeutics Inc (FSTX) are Rs -- and Rs -- as of 29-Aug-2026.
What is the market cap of FStar Therapeutics Inc (FSTX)?
FStar Therapeutics Inc (FSTX) has a market capitalisation of $ 157 Mln as on 17-Mar-2023. As per SEBI classification, it is a company.
Should I invest in FStar Therapeutics Inc (FSTX)?
Before investing in FStar Therapeutics Inc (FSTX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.